Recently Khor and associates reported on the immunohistochemical results for Bcl-2 in 586 high-risk prostate cancer patients prospectively randomized to the Radiation Therapy Oncology Group (RTOG) trial 92-02 in which XRT was given in conjunction with a short course (STAD) or long course (LTAD) of androgen deprivation therapy. This evidence concerns the gene BCL2 and prostate carcinoma.